Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as rilapladib
SB-659032 · 5 trials · 3 indications
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42 and Abeta40 are summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42/Abeta40 ratio is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
CSF tau and P-tau were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF tau and P-tau was summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
The WM/EF composite score was comprised of 5 functional tests including 1) Controlled oral word association which measured language fluency, planning and working memory, 2) Category naming: It measures semantic fluency, planning and working memory, 3) One-back: This is a measure of working memory. 4) Trail B: This is a measure of motor speed, visual scanning, and visual-motor integration. This test required attention and cognitive flexibility. 5) Go No-Go task: This test evaluate accuracy and reaction time for each response. The composite score calculated by standardizing the total score: sum of all responses obtained from these 5 functional test by using the formula (Total score of ITT population at baseline - Total score at Week 24) /standard deviation of mean total mean score at baseline. The observed composite score ranged from minimum -1.474 and maximum 1.596. Lower score means better cognitive status. Change from Baseline was calculated as post-dose visit minus Baseline value.
Percent maximum platelet aggregation following ADP- and collagen-induced aggregation
Urinary 11-dehydrothromboxane B2 and blood CD62 concentrations
| Arm | Type | Description |
|---|---|---|
| 250mg rilapladib | EXPERIMENTAL | Experimental drug |
| placebo | PLACEBO_COMPARATOR | Placebo comparator |
| rilapladib | ACTIVE_COMPARATOR | 250 mg/day |
| SB-659032 | EXPERIMENTAL | 250 mg non-enteric coated SB-659032 |
| Name | Type | Description |
|---|---|---|
| 250mg rilapladib | DRUG | Experimental Drug |
| placebo | DRUG | Placebo comparator |
| rilapladib | DRUG | 250 mg oral dose once daily |
| 18F Fluorodeoxylucose (FDG)-PET | OTHER | FDG-PET |
| Rilapladib (SB-659032) | DRUG | - |
| SB-659032 | DRUG | - |
| SB659032 | DRUG | single dose |
Inclusion Criteria: 1. A clinical diagnosis of possible Alzheimer's disease in accordance with the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with radiological (Magnetic Resonance Imaging \[...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
SB-659032 is an investigational small molecule developed by GSK plc for atherosclerosis, a cardiovascular condition. It has been studied in Phase 1 clinical trials assessing its effects on platelet function and platelet aggregation. It is not an approved therapy and remains in early clinical development.
SB-659032 was studied in atherosclerosis research, specifically to assess its effect on platelet function and platelet aggregation in healthy volunteers. Both Phase 1 trials enrolled participants with atherosclerosis listed as the condition. It is investigational and has not been approved for any use.
SB-659032 is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 1 clinical program evaluating the compound in platelet function and platelet aggregation studies. No other developer or partnership is associated with the asset.
SB-659032 is in Phase 1. Two Phase 1 trials have been completed, with no active trials ongoing. The program enrolled 40 participants total across both studies. SB-659032 is investigational and has not received FDA approval.
SB-659032 has been evaluated in two completed Phase 1 trials: NCT01750827, a study assessing the effect of SB 659032 on platelet function in the United States with 14 participants, and NCT01745458, the SB-659032 Platelet Aggregation Study in Australia with 26 participants. Both were randomized, double-blind, and placebo-controlled.
Yes, SB659032 is an alternative spelling of SB-659032, referring to the same investigational compound. The hyphenated form SB-659032 appears in trial records, while SB659032 is used without the hyphen. Both names identify the same GSK small molecule studied in Phase 1 for atherosclerosis.